Placeholder

Gene Therapy Research Makes Progress

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

Product Description

With all the progress that has been made in genomics, targeting therapies to correct the defective genes responsible for disease seems quite realistic. But developing commercial gene therapies to treat diseases through modifying the expressions of an individual’s genes or correcting abnormal genes has proven to be more difficult.
While hundreds of treatments that involve the administration of DNA to treat many different diseases are currently being investigated as gene therapy candidates, the Food and Drug Administration has yet to approve any human gene therapy products. In fact, only one gene therapy product has been approved by any regulatory agency, and that product is Gendicine. The approval was granted in October 2003 in China, for the treatment of head and neck squamous cell carcinoma…

Sidebars:
Factors Affecting Gene therapy Progress
Factors Influencing The Gene Therapy Market
Gendicine Stands Alone

Experts on this Topic
Joyce L. Frey-Vasconcells, Ph.D. Executive Director, PharmaNet Consulting, Princeton, N.J.; PharmaNet Consulting, part of PharmaNet Development Group, provides solutions to the many potential obstacles inherent in designing, planning, and coordinating regional and global clinical trial programs. For more information, visit pharmanet.com.
Jeffrey M. Ostrove, Ph.D. President and CEO, Ceregene Inc., San Diego; Ceregene is a biotechnology company focused on the development of gene therapies for neurodegenerative disorders. For more information, visit ceregene.com.
H. Stewart Parker. President and CEO, Targeted Genetics Corp., Seattle; Targeted Genetics is a biotechnology company committed to the development of innovative targeted molecular therapies for the prevention and treatment of acquired and inherited diseases with significant unmet medical need. For more information, visit targen.com.
Christopher J. Reinhard. Chairman, CEO, and President, Cardium Therapeutics Inc., San Diego; Cardium Therapeutics is a medical technology company primarily focused on the development and commercialization of novel biologic therapeutics and medical devices for cardiovascular and ischemic disease. For more information, visit cardiumthx.com.
Sam Wadsworth, Ph.D. Group VP, Translational Research, Genzyme Corp., Cambridge, Mass.; Genzyme is a biotechnology company focused on rare inherited disorders, kidney disease,
orthopedics, transplant, cancer, and diagnostic testing. For more information, visit genzyme.com.

FEEDBACK